NCT06948786 2026-04-22Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialUniversity of WashingtonPhase 2 Recruiting22 enrolled
NCT05990465 2026-02-23LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesMedical College of WisconsinPhase 1 Recruiting12 enrolled